| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9019c0ce5cb7b82c85e121f6cac86dce |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6949
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-765 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate |
2002-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f4c0744b7c30bb70d2e929c9ecd7d71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_153ca176684fe9511cec3b3c375bfa28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bfa674d82711bcd346b37dbab3457f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_627ab8b7a552ba9a8e3d653de383549c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b499287558d6104419b0848a782eabe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4ddee8cd2469908429f17521bd323eb |
| publicationDate |
2004-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1405644-A1 |
| titleOfInvention |
Tissue-specific transporter inhibitor |
| abstract |
The present invention is to provide a tissue-specificntransporter inhibitor which is not absorbed through thendigestive tract and can prevent deterioration in the QOL of anpatient caused by diet therapy, and a therapeutic drug forntissue dysfunction diseases and a therapeutic drug fornsuppressing the progress of chronic renal failure containingnthe inhibitor as an active ingredient. A tissue-specificntransporter inhibitor which is not absorbed through thendigestive tract is constructed by introducing a dipeptide whichnis a ligand of an oligopeptide transporter 1 into ansupramolecular structure polyrotaxane wherein itsnstructurally modified active residue is expected to benexcellent in the interaction with a transmembrane transporter. |
| priorityDate |
2001-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |